Company: PACB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001299130-25-000156
Chunk: 18

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 18
---
 30, 2025$— Changes to the fair value are recorded as change in fair value of contingent consideration in the condensed consolidated statements of operations and comprehensive loss.Cash, Cash Equivalents, Restricted Cash, and InvestmentsThe following tables summarize our cash, cash equivalents, restricted cash, and investments:As of June 30, 2025(In thousands)AmortizedCost GrossunrealizedgainsGrossunrealizedlossesFairValueCash and cash equivalents$54,803 $— $— $54,803 Investments:Corporate debt securities 30,939 130 (5)31,064 U.S. government & agency securities228,726 191 (49)228,868 Total investments 259,665 321 (54)259,932 Total cash, cash equivalents and investments $314,468 $321 $(54)$314,735 Short-term restricted cash$300 $— $— $300 Long-term restricted cash$1,532 $— $— $1,532 As of December 31, 2024(In thousands)AmortizedCostGrossunrealizedgainsGrossunrealizedlossesFairValueCash and cash equivalents$55,370 $— $— $55,370 Investments:Corporate debt securities46,746 184 (25)46,905 U.S. government & agency securities287,393 418 (155)287,656 Total investments334,139 602 (180)334,561 Total cash, cash equivalents and investments$389,509 $602 $(180)$389,931 Short-term restricted cash$690 $— $— $690 Long-term restricted cash$1,532 $— $— $1,532 

Q2 Fiscal 2025 Form 10-Q11

The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of June 30, 2025:(In thousands)Fair ValueDue in one year or less $214,595 Due after one year through five years 48,816 Total$263,411 Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.Investment income included in other income, net